1. Prevalence and incidence of diabetic retinopathy (DR) in the UK population of Gloucestershire.
- Author
-
Scanlon PH, Nevill CR, Stratton IM, Maruti SS, Massó-González EL, Sivaprasad S, Bailey C, Ehrlich M, and Chong V
- Subjects
- Aged, Disease Progression, England epidemiology, Female, Humans, Incidence, Male, Mass Screening statistics & numerical data, Middle Aged, Prevalence, Retrospective Studies, Risk Factors, Diabetic Retinopathy epidemiology
- Abstract
Purpose: To estimate prevalence and incidence of diabetic retinopathy (DR) in a UK region by severity between 2012 and 2016 and risk factors for progression to proliferative DR (PDR)., Methods: Electronic medical records from people with diabetes (PWD) ≥18 years seen at the Gloucestershire Diabetic Eye Screening Programme (GDESP) and the hospital eye clinic were analysed (HEC). Prevalence and incidence of DR per 100 PWD (%) by calendar year, grade and diabetes type were estimated using log-linear regression. Progression to PDR and associated risk factors were estimated using parametric survival analyses., Results: Across the study period, 35 873 PWD had at least one DR assessment. They were aged 66 (56-75) years (median (interquartile range)), 57% male, 5 (1-10) years since diabetes diagnosis, 93% Type 2 diabetes. Prevalence of DR decreased from 38.9% (95% CI: 38.1%, 39.8%) in 2012 to 36.6% (95% CI: 35.9%, 37.3%) in 2016 (p < 0.001). Incidence of any DR decreased from 10.9% (95% CI: 10.4%, 11.5%) in 2013 to 8.5% (95% CI: 8.1%, 9.0%) in 2016 (p < 0.001). Prevalence of PDR decreased from 3.5% (95% CI: 3.3%, 3.8%) in 2012 to 3.1% (95% CI 2.9%, 3.3%) in 2016 (p = 0.008). Incidence of PDR did not change over time. HbA
1c and bilateral moderate-severe NPDR were statistically significant risk factors associated with progression to PDR., Conclusions: Incidence and prevalence of DR decreased between 2012 and 2016 in this well-characterized population of the UK., (© 2021 Boehringer Ingelheim International GmBH. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.)- Published
- 2022
- Full Text
- View/download PDF